The combination of Astrazeneca and Sputnik Light gave an excellent result | Auspicious study data

The Russian direct investment fund (RDIF, Sovereign Fund of the Russian Federation), the companies AstraZeneca and R-PHARM conducted a combined application trial which resulted in an increase in “four times and more” of neutralizing antibodies in 85% of participating volunteers. The study was carried out with the dose developed by the Anglo-Swedish laboratory jointly with the University of Oxford and the Sputnik light del Instituto Gamalea.

Preliminary data from study carried out in the Republic of Azerbaijan they are based on the observations of the first 20 study participants who received the two inoculants. The first component used was the AstraZeneca vaccine and the second Sputnik Light with a dose interval of 29 days.

According to the results of the interim analysis, 85% of the volunteers experienced a four-fold or greater increase in neutralizing antibodies against the spike protein (S protein) of the SARS-CoV-2 virus on day 57 of follow-up.

Research in Azerbaijan started in February 2021 and so far 100 volunteers are participating in the study. Intermediate analysis of the data also previously demonstrated the production of antibodies against the spike protein (S protein) of the SARS-CoV-2 virus, from which the virus begins to reproduce in the body.

“In 100% of the volunteers, as well as the high safety rates of the combined use of drugs: there were no serious adverse events, nor cases of coronavirus infection after vaccination,” says the report. of RDIF.